Longevity Science Update July 2026: Peptides, NAD Risks, PCSK9 and GLP-1
Matt Kaeberlein and India-based longevity clinician Marcus walk through the biggest longevity medicine stories of July 2026. They cover the FDA peptide compounding vote, a tragic NAD infusion death, the shaky NAD precursor evidence, the first oral PCSK9 inhibitor, triple-agonist weight-loss drugs, and how to prioritize diet.
Overview
In this July 2026 Longevity Science Update, Matt Kaeberlein is joined by Marcus, a longevity clinician based in India, after Brian Kennedy has to cancel. They open with the FDA committee vote that recommended returning six of seven experimental peptides, including BPC-157 and TB500, to the list pharmacies may compound, and stress that this is a regulatory reclassification, not proof of safety or efficacy.
Both agree peptides look incremental at best compared with diet, exercise, sleep, hormones, or GLP-1 drugs. The conversation turns somber with the death of a 27-year-old woman in New York shortly after an NAD infusion given at an unlicensed clinic, prompting a hard look at why healthy young people receive NAD drips at all. From there they dissect the shaky NAD precursor literature in mice and humans, questioning whether NAD even declines with age.
They review the newly approved oral PCSK9 inhibitor Enlicitide, aggressive LDL and ApoB lowering, and emerging ways to move Lp(a). On body weight, they explore the triple-agonist retatrutide, its fat-loss promise, and the fight to classify it as a biologic. They close with diet priorities, Marcus's high-altitude marathon and India white paper, and a candid tour of both men's supplement stacks and altitude therapies.
Key quotes
5These things have some biological activity, but they don't move the needle the way diet, exercise, sleep, hormones, or GLPs do. They're incremental at best.
An unnecessary intervention with unclear benefit that causes you to feel like you're having a heart attack should give responsible medical professionals pause.
There's lots of smoke. I don't know if there's any fire, and I've been saying that for a decade, which makes me think there might not be any fire.
We have the toolkit now to prevent heart disease from being a major killer. It's a matter of getting it to the right people at the right time at a reasonable cost.
What you eat is way more important than when you eat. Stop confusing people.
Key ideas
8FDA committee moves peptides back toward compounding
An FDA advisory committee recommended returning six of seven previously removed experimental peptides, including BPC-157 and TB500, to the list pharmacies may compound. The lone rejection was one lesser-known peptide, and any formal change is still many months away.
Reclassification is not approval
The FDA's own scientists advised against the move, noting no new safety or efficacy data. Allowing compounding does not make these peptides FDA-approved, a distinction the hosts worry the public will miss.
Peptides look incremental at best
Both men have tried peptides like BPC-157 and TB500 personally and in patients without seeing meaningful biomarker or subjective change. The hope is that legal compounding reduces the dangerous black market, though cheaper illicit product may persist.
A tragic NAD infusion death
A 27-year-old woman in New York died shortly after an NAD infusion administered by someone not licensed to practice medicine in the US. The case underscores how unregulated wellness clinics offering IV drips can carry real, sometimes fatal, risk.
The NAD precursor evidence is shaky
Early mouse lifespan signals for NR and NMN, from the Auwerx and Sinclair labs, largely failed rigorous replication such as the ITP. The literature is a mix of weak signal and irreproducible results, making confident conclusions hard.
Does NAD even decline with age?
A central claim of NAD proponents, that NAD falls with age, is unclear in humans. Newer data suggest blood NAD may not decline with age at all, and the hosts expect other tissues may follow.
An oral PCSK9 inhibitor arrives
The FDA approved Enlicitide, the first oral PCSK9 inhibitor, offering roughly 50 to 60 percent LDL reduction comparable to injectable Repatha without the needle. It was approved on an LDL endpoint, so cardiovascular outcome data is still pending.
Retatrutide and the fat-loss promise
Retatrutide, a triple agonist hitting GLP-1, GIP, and the glucagon receptor, is reported to drive large weight loss weighted toward fat rather than muscle. Its regulatory classification as a small molecule versus a biologic is being contested, with real pricing and patent stakes.
Practical takeaways
6- 1
Think twice about NAD drips 30:00
For healthy young people there is no convincing rationale for high-dose NAD infusions, and a subset feel intense chest tightness. If you explore NAD at all, oral precursors are the safer, lower-dose format to discuss with a clinician.
- 2
Set realistic expectations for precursors 48:00
Oral NAD precursors appear reasonably safe, but effect sizes in humans are small and hard to separate from sleep, diet, and other habits. Treat any benefit as incremental rather than transformative.
- 3
Lower LDL and ApoB early and often 58:00
Aggressive lipid lowering with statins, ezetimibe, and PCSK9 inhibitors is a powerful, well-supported way to protect the heart. An oral PCSK9 option can help people who fear or dislike injections stay on therapy.
- 4
Track Lp(a) over time 1:01:00
Long thought to be fixed by genetics, Lp(a) appears to shift with lifestyle change and lipid-lowering therapy in some people. Serial measurement, not a single lifetime test, may reveal that movement.
- 5
Fix what you eat first 1:10:00
Prioritize food quality first, quantity second, and timing last. A whole-food, protein-adequate diet tends to make portion size take care of itself, while time-restricted eating offers little on a poor diet.
- 6
Respect the risks of altitude therapies 1:14:00
Hyperbaric oxygen and intermittent hypoxic therapy are significant physiological perturbations. Use reputable equipment, and be cautious with hypoxic training if you have respiratory or cardiovascular conditions.
Topics & chapters
14Intro and Brian's cancellation
Matt welcomes Marcus for a July science update after Brian Kennedy has to cancel.
The FDA peptide compounding vote
A committee recommends returning six of seven experimental peptides to the compounding list.
Was the decision evidence-based?
FDA scientists advised against it, and reclassification is not the same as approval.
Peptide efficacy and the black market
Personal experiments with BPC-157 and TB500 and hopes of cleaner, legal product.
An NAD infusion tragedy in New York
A young woman dies after an NAD drip at an unlicensed clinic, raising safety alarms.
Do NAD drips make sense?
Intense chest-tightness reactions and the lack of rationale for healthy young people.
NAD precursors: the mouse data
NR and NMN lifespan claims, the Auwerx and Sinclair labs, and ITP replication.
Does NAD decline with age?
Why the core human claim is unclear, and new blood data suggesting it may not.
NAD precursors in the clinic
How Marcus used precursors in frail older adults and athletes, and why he paused.
PCSK9 inhibitors and oral Enlicitide
Mechanism, LDL reduction, and the toolkit to make heart disease preventable.
Lp(a) and serial tracking
Evidence that Lp(a) can move with lifestyle and lipid-lowering therapy over time.
GLP-1 generations and retatrutide
From single to triple agonists, fat-loss potential, and the biologic classification fight.
Diet: what, how much, and when
Ranking food quality, quantity, and timing, with the CALERIE and time-restricted data.
Marathon, altitude therapy, and stacks
Marcus's high-altitude race and India white paper, plus both men's supplements, HBOT, and IHT.